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Editorial on the Research Topic
Novel Immunotherapies Against Envenomings by Snakes and Other Venomous Animals
Globally, several million people fall victim to animal envenomings each year. These envenomings
are caused by snakes, scorpions, spiders, bees, and other venomous animals (Pucca et al.), which
are able to inflict bites and stings, which inject venoms, mixtures of protein-based toxins, into
their victims and prey. Since the late eighteenth century, the first-choice treatment for severe
animal envenomings has been antivenoms, which consist of polyclonal antibodies or antibody
fragments isolated from the serum or plasma of animals hyper-immunized with venoms. These
essential medicines are invaluable in saving the lives and limbs of patients worldwide. However,
these “conventional” antivenoms are burdened with a number of disadvantages, such as a high
content of non-neutralizing antibodies, a propensity to induce adverse reactions (including serum
sickness and anaphylaxis), and a relatively high cost of manufacture compared to many other
routinely used therapeutics (1). In recent decades, many new biotechnologies have emerged,
which have been successfully employed to develop breakthrough therapies within oncology,
autoimmunity, and infectious diseases. These biotechnologies present an opportunity for the
field of envenoming therapy, and antivenom researchers have therefore started to apply these
new approaches with the goal of increasing the efficacy of plasma-derived antivenoms through
innovative immunization approaches (2), or by utilizing recombinant DNA technology and
antibody discoverymethodologies to generate recombinant antivenoms with improved efficacy and
safety profiles.
This Research Topic presents two reviews and two original research articles that exhibit
prominent and recent examples of the developments within novel immunotherapies against
envenomings by snakes and other venomous animals. In Pucca et al., the history of envenoming
therapies is reviewed with a focus on the key developments in the life sciences that led to the
generation of the first antivenoms, as well as their subsequent refinement and optimization.
It underscores the impact of basic immunological research within the field, as well as
the contributions generated within antivenom research, which led to the development of
immunological methods and novel therapeutics based on monoclonal antibodies that are now
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utilized across almost all fields of medicine. This review further
provides perspectives on the advances in biotechnology in the
last decades, which have influenced the academic research agenda
in antivenom research, and discusses how different scientific
breakthroughs in synthetic biology, antibody technologies,
immunology, and molecular biology, such as phage display
technology, may be exploited in the development of improved,
next-generation envenoming therapies.
In de Castro et al., an example is provided of how knowledge
of venom biology and new immunization approaches can be
harnessed in the development of improved serotherapies against
envenomings by Micrurus spp. (coral snakes). Here, a combined
immunization protocol, using priming doses of M. frontalis
venom and booster doses of synthetic B-cell epitopes derived
from M. corallinus three-finger toxins and phospholipases
A2, elicited a humoral response against both venoms in a
rabbit model. The raised sera displayed relevant cross-reactivity
against venoms from other Micrurus species (M. altirostris,
M. lemniscatus, M. spixii, and M. surinamensis) and were
demonstrated to be able to neutralize PLA2 activity ofM. frontalis
andM. corallinus venoms. In vivo, the sera completely protected
mice from a challenge with 1.5 median lethal dose (LD50) of M.
corallinus venom and protected 50% of mice challenged with 1.5
LD50 ofM. frontalis venom.
Bailon-Calderon et al. describe a promising example of
the utilization of antibody technologies. In their work, a
set of nanobodies was developed from a library of a Lama
glama immunized with the venom of Bothrops atrox, a
viperid of utmost medical relevance in South America.
Several of the obtained recombinant nanobodies showed
neutralizing ability toward hemorrhagic and myotoxic venom
components, which are responsible formajor local tissue damage.
The study further highlights the valuable potential of these
innovative biotherapeutics, bringing them one step closer to
clinical application.
Finally, Pucca et al. provide a comprehensive overview of
the scientific literature surrounding bee venom toxinology and
the treatment against bee stings. Here, the epidemiology of Apis
spp. (bees) is presented with a special focus on the species
Apis mellifera (Africanized bee), which is a hybrid species of
the African and European honey bees that cause a significant
number of severe envenomings, some of which have resulted in
human fatalities. Further, all proteinaceous components of bee
venom are presented with a discussion on the two main toxic
components, phospholipase A2 andmelittin, and their synergistic
toxic function in victims. The review concludes with a detailing
of how bee stings are currently only treated symptomatically, and
that opportunities exist for developing recombinant antivenoms
against bee envenomings.
The field of next-generation antivenoms has recently gained
increased interest, and technological advancements now enable
researchers to undertake the ambitious endeavor of developing
improved therapeutic interventions against animal envenomings.
This trend will likely continue for the years to come, as such
efforts are officially supported by the recently published strategy
from the World Health Organization (3). Next-generation
antivenom research is still a rather nascent field. However, within
the next two decades, it is predicted that this area of research will
experience significant development and innovation.
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